Sanofi licenses 5 drugs to Covis

04/8/2013 | Pharmaceutical Business Review Online · Drug Store News

Switzerland's Covis Pharma agreed to acquire the U.S. commercial rights to five drugs from Sanofi-Aventis and its units. The deal covers the prostate cancer drug Nilandron; Plaquenil, a drug for malaria, lupus and arthritis; amyotrophic lateral sclerosis drug Rilutek; Uroxatral, a drug for enlarged prostate; and high-potassium treatment Kayexalate. Sanofi keeps the products' rights elsewhere in the world.

View Full Article in:

Pharmaceutical Business Review Online · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC